Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Laboratory Developed Tests Market Size & Share 2026-2035
Report ID: GMI9340
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Laboratory Developed Tests Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Laboratory Developed Tests Market Size
The laboratory developed tests market was valued at USD 19.70 billion in 2025, is expected to reach USD 21.81 billion in 2026, is projected to expand at a 10.4% CAGR (2026–2035), and is forecast to reach USD 53.35 billion by 2035. Laboratory developed tests are high-complexity in-vitro diagnostic services designed, validated, and performed within a single clinical laboratory, spanning molecular diagnostics, sequencing panels, immunoassays, mass spectrometry, cytogenetics, and specialized assays.
Laboratory Developed Tests Market Key Takeaways
Market Leader: Labcorp led with over 15.5% market share in 2025.
Leading Players: Top 5 players in this market include Labcorp, Quest Diagnostics, Natera, Mayo Clinic Laboratories, Myriad Genetics, which collectively held a market share of 45.5% in 2025.
The laboratory developed tests market is expanding because clinical decision-making increasingly requires diagnostic specificity that standardized commercial kits cannot provide across oncology, rare disease, pharmacogenomics, and prenatal medicine. Laboratories with established assay-development, bioinformatics, and clinical-validation capabilities are positioned to address these unmet diagnostic requirements while translating emerging biomarkers into clinical services.
GMI Analyst View
Based on input from industry leaders, the laboratory developed tests market generated USD 17.80 billion in revenue in 2024 — a figure that benchmarks the pace of molecular and genomic test adoption immediately preceding the 2025 base year. We view this progression as evidence that advanced diagnostic ordering was already becoming embedded across oncology, reproductive health, and precision-medicine workflows before the current forecast period.
Laboratory Developed Tests Market Trends, Growth Drivers & GMI Forecast Outlook
The market outlook is shaped by a widening mismatch between the complexity of clinically actionable biomarkers and the breadth of commercially available diagnostic kits. Rising cancer burden and laboratory investment in specialized workflows support demand, while reimbursement pressure and validation requirements influence the pace at which laboratories can expand menus.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Cancer care increasingly depends on molecular characterization at the point where treatment selection, recurrence monitoring, and hereditary-risk assessment converge. This creates a durable role for laboratories able to configure assays around evolving biomarkers, specimen types, and physician protocols rather than relying on fixed commercial test menus.
The expansion of guideline-supported sequencing is particularly consequential because it converts specialized genomic testing from an optional referral pathway into a more routine component of care. ESMO's updated recommendations broadened the set of advanced solid-tumor settings in which routine NGS is relevant, strengthening the physician-ordering base for specialty laboratory portfolios [2]ESMO Precision Medicine Working Group. "Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Advanced Cancer in 2024." annalsofoncology.org. Rare-disease and pharmacogenomic services further diversify demand because their clinical requirements often remain too fragmented for broad commercial kit development.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Reimbursement uncertainty affects laboratories unevenly. National networks and specialized providers can spread scientific, operational, and logistics costs across broader testing volumes, whereas independent and community laboratories often must make narrower capital-allocation choices. Fee pressure can therefore delay investment in new panels even when clinical need is clear.
Analytical validation is also a commercial constraint rather than a purely technical obligation. Precision, accuracy, sensitivity, and reportable-range verification require laboratory personnel, specimens, instrumentation time, and documented quality systems. The resulting development cycle favors providers with established scientific infrastructure and can slow the conversion of emerging biomarkers into widely available testing services.
GMI Analyst View
We believe the market's defining tension is not whether physicians will require more sophisticated testing, but whether reimbursement and laboratory economics will support equally broad service expansion. Demand is moving toward complex genomic applications, while the ability to monetize that demand will remain differentiated by laboratory scale, specialization, and payer access.
Laboratory Developed Tests Market Segment Analysis
By Technology
Molecular diagnostics accounted for 35.0% of laboratory developed tests market revenue in 2025 and is projected to generate USD 17.97 billion by 2035. PCR-based and related molecular workflows retain broad clinical relevance across infectious disease, oncology, microbiology, and pharmacogenomic testing, giving the category a large installed base and recurring physician-ordering demand.
Next-generation sequencing is forecast to reach USD 14.12 billion by 2035 and is expected to expand at a 12.6% CAGR (2026–2035). Its ability to interrogate multiple genomic targets from limited clinical material makes it central to tumor profiling, hereditary cancer assessment, and rare-disease testing, where laboratory-configured panels can be adapted to evolving clinical evidence.
Immunoassay-based testing generated USD 3.54 billion in 2025 and is expected to represent 19.1% of segment revenue by 2035. The category remains important for autoimmune, endocrine, allergy, and other applications in which laboratories can tailor analyte combinations to local referral patterns and disease-specific diagnostic needs.
Mass spectrometry is projected to reach USD 3.18 billion by 2035 and held a 6.0% revenue share in 2025. Its competitive position rests on analytical precision in therapeutic drug monitoring, toxicology, and metabolomics, where sensitivity and selectivity requirements can exceed the practical limits of standard immunoassay formats.
Cytogenetics represented 4.0% of revenue in 2025 and is projected to advance at a 10.5% CAGR (2026–2035). FISH panels, chromosomal microarrays, and karyotyping continue to support prenatal, hematologic, hereditary cancer, and rare-disease workflows in which clinically meaningful interpretation depends on laboratory expertise as much as on the assay platform.
By Application
Oncology generated USD 7.48 billion in 2025 and is forecast to reach USD 21.49 billion by 2035. The application benefits from the clinical need to align treatment decisions with tumor-specific molecular findings, creating sustained demand for somatic profiling, liquid biopsy, hereditary-risk testing, and other laboratory-configured genomic services.
Infectious diseases are projected to reach USD 8.32 billion by 2035 and accounted for 20.0% of laboratory developed tests market revenue in 2025. Demand is supported by complex pathogen identification, syndromic testing, and specialized microbiology workflows for patients whose clinical presentation requires broader analyte coverage than conventional test kits provide.
Genetic and rare disorders testing is projected to generate USD 9.14 billion by 2035 and is expected to grow at a 12.0% CAGR (2026–2035). The segment is structurally supported by the large number of rare phenotypes for which commercial diagnostic options are unavailable, positioning specialty and academic laboratories as key providers of exome- and genome-based services.
Autoimmune and inflammatory testing generated USD 1.57 billion in 2025 and is expected to account for 7.0% of revenue by 2035. Customized antibody and biomarker panels retain value where disease presentation is heterogeneous and clinicians require a testing approach tailored to rheumatologic, dermatologic, or endocrine diagnostic pathways.
Prenatal and neonatal testing accounted for 6.0% of revenue in 2025 and is forecast to expand at a 12.4% CAGR (2026–2035). Greater use of non-invasive prenatal testing, carrier screening, and genomic neonatal diagnostics is reinforcing the need for laboratory services able to provide broader clinical coverage than standardized assay formats.
Pharmacogenomics is forecast to reach USD 3.12 billion by 2035 and is expected to grow at a 12.3% CAGR (2026–2035). Demand reflects the integration of medication-response information into oncology, psychiatric, and cardiovascular care, where clinicians often need multi-gene panels that extend beyond individual commercial test offerings.
Neurology and mental health diagnostics generated USD 394 million in 2025 and are forecast to reach USD 1.28 billion by 2035. Growth is supported by emerging biomarker applications, pharmacogenomic-guided treatment selection, and the need for specialized assays in neurodegenerative and central nervous system conditions.
By End User
Private and independent reference laboratories are projected to generate USD 19.81 billion by 2035, compared with USD 7.48 billion in 2025. Their scale in specimen logistics, specialized personnel, payer contracting, and high-complexity infrastructure supports broad deployment of molecular, genomic, and oncology-focused laboratory developed tests.
Hospital-based laboratories held a 30.0% revenue share in 2025 and are forecast to grow at a 9.7% CAGR (2026–2035). Health systems are increasingly internalizing time-sensitive molecular and genomic workflows to reduce turnaround times, strengthen clinician-laboratory coordination, and differentiate their diagnostic service lines.
Specialty diagnostic laboratories accounted for 22.0% of revenue in 2025 and are forecast to reach USD 12.83 billion by 2035. Disease-focused laboratories can build defensible positions through concentrated expertise in areas such as reproductive health, oncology, neurology, and dermatopathology, where test interpretation and physician relationships are critical commercial assets.
Academic and research institutions generated USD 1.37 billion in 2025 and are expected to expand at a 10.5% CAGR (2026–2035). Their clinical-trial infrastructure and scientific depth enable early translation of novel biomarkers into validated patient-testing services, particularly in rare disease, advanced oncology, and emerging neurological applications.
Direct-to-consumer testing providers are projected to generate USD 2.03 billion by 2035 and are forecast to advance at a 13.2% CAGR (2026–2035). Consumer interest in wellness genomics, pharmacogenomics, and targeted health-risk assessment is expanding the role of CLIA-certified laboratories that can support compliant direct-access testing models.
GMI Analyst View
We see the segment mix shifting toward platforms and applications where clinical complexity is increasing faster than commercial-kit standardization. Sequencing, oncology, rare disease, and pharmacogenomics are not simply high-growth categories; they represent diagnostic settings in which laboratory-developed configurations remain structurally necessary to meet physician expectations.
Laboratory Developed Tests Market Regional Analysis
North America Laboratory Developed Tests Market Analysis
North America generated USD 11.42 billion in 2025 and is forecast to reach USD 28.32 billion by 2035. The laboratory developed tests market in the region is supported by deeply established reference-laboratory networks, mature physician ordering behavior, CLIA-certified infrastructure, and a large base of oncology and genomic testing demand.
U.S.
The U.S. generated USD 10.85 billion in 2025 and is projected to reach USD 26.48 billion by 2035. Its leadership reflects the concentration of national reference laboratories, academic medical centers, payer coverage pathways, and specialized genomics providers capable of developing and validating complex diagnostic services.
Canada
Canada accounted for 2.9% of global revenue in 2025 and is projected to grow at a 12.2% CAGR (2026–2035). Provincial health systems are progressively incorporating molecular and genomic testing into oncology, prenatal, and rare-disease pathways, with health-technology assessment and clinical-evidence development influencing the pace of adoption.
Europe Laboratory Developed Tests Market Analysis
Europe generated USD 4.33 billion in 2025 and is forecast to reach USD 11.24 billion by 2035. The laboratory developed tests market in Europe operates across varied reimbursement and laboratory-quality frameworks, with national genomics strategies and public health-system capacity shaping adoption more strongly than a single regional model.
Germany
Germany generated USD 887 million in 2025 and is projected to reach USD 2.31 billion by 2035. Its biomedical research base and reimbursement mechanisms for qualified laboratory services support high-complexity molecular and genomic testing across university hospitals and commercial reference laboratories.
UK
The UK represented 3.5% of global revenue in 2025 and is forecast to grow at a 10.4% CAGR (2026–2035). The NHS Genomic Medicine Service provides a structured delivery framework for whole-genome sequencing and targeted panel testing across rare disease, oncology, and reproductive genetics.
France
France is forecast to reach USD 1.48 billion by 2035 and accounted for 3.0% of global revenue in 2025. Nationally accredited biological medical laboratories and genomics initiatives support the clinical translation of complex molecular testing, particularly through designated genomic medicine centers.
Asia Pacific Laboratory Developed Tests Market Analysis
Asia Pacific generated USD 2.75 billion in 2025 and is forecast to reach USD 10.23 billion by 2035, representing a significant share of global revenue in the forecast-end year. The laboratory developed tests market in Asia Pacific is gaining momentum as clinical genomics investment, private diagnostic capacity, and oncology testing needs rise across major healthcare markets.
China
China generated USD 1.08 billion in 2025 and is forecast to expand at a 16.4% CAGR (2026–2035). Government support for clinical genomics, growing oncology demand, and the expansion of domestic sequencing capacity are strengthening the commercial foundation for specialized laboratory testing.
Japan
Japan accounted for 4.0% of global revenue in 2025 and is projected to generate USD 2.38 billion by 2035. Its established clinical-laboratory sector and national health-insurance coverage of selected genomic applications create a stable platform for molecular diagnostics and precision-oncology services.
India
India generated USD 296 million in 2025 and is projected to grow at a 14.8% CAGR (2026–2035). Private reference-laboratory expansion, increasing clinician awareness of hereditary disease testing, and demand for accessible genomic services are broadening the country's high-complexity diagnostic base.
Latin America Laboratory Developed Tests Market Analysis
Latin America generated USD 788 million in 2025 and is forecast to reach USD 2.23 billion by 2035. The laboratory developed tests market in the region is concentrated in larger healthcare economies, where private laboratories and hospital-affiliated diagnostic centers are expanding access to oncology, infectious-disease, prenatal, and molecular testing services.
Brazil
Brazil generated USD 394 million in 2025 and is projected to grow at an 11.5% CAGR (2026–2035). Its private healthcare sector and urban diagnostic networks are expanding molecular and NGS-based test offerings, while broader public-sector adoption remains a longer-term opportunity.
Further, regional countries such as Mexico and Argentina are also key contributors in the Latin America region along with other countries captured within Rest of Latin America. Regional expansion is supported by private diagnostic capacity, specialist referrals, and growing demand for oncology and prenatal testing among patients with access to private coverage.
Middle East & Africa Laboratory Developed Tests Market Analysis
Middle East & Africa is projected to reach USD 1.33 billion by 2035 and is forecast to grow at a 12.9% CAGR (2026–2035). The laboratory developed tests market is advancing through healthcare-infrastructure investment, genomic-medicine programs, and the development of advanced molecular laboratory capacity in Gulf countries.
Saudi Arabia
Saudi Arabia accounted for 0.6% of global revenue in 2025 and is forecast to expand at a 14.1% CAGR (2026–2035). Healthcare transformation initiatives, hereditary-disease screening needs, and investment in government hospital laboratories are supporting demand for genomic and molecular testing services.
UAE
The UAE generated USD 98 million in 2025 and is forecast to grow at a 14.0% CAGR (2026–2035). Investment by health authorities and private providers is positioning the country as a regional hub for precision medicine, advanced diagnostics, and laboratory services supporting domestic and cross-border patient demand.
GMI Analyst View
We expect regional competition to be defined by each market's ability to combine laboratory quality systems, specialist clinical expertise, reimbursement support, and genomic infrastructure. North America remains structurally advantaged, but Asia Pacific has the strongest strategic expansion opportunity as diagnostic capability catches up with substantial unmet demand for molecular and genomic testing.
Laboratory Developed Tests Market Share & Competitive Landscape
The five leading providers held a combined 45.5% share of laboratory developed tests market revenue in 2025. Laboratory developed tests market share remains dispersed beyond these large providers because assay development, clinical validation, referral relationships, and local laboratory accreditation create durable advantages for hospital-based, regional, specialty, and academic operators.
Labcorp held a 15.5% revenue share in 2025. Its competitive position is underpinned by national specimen logistics, broad specialty-test menus, and scale across oncology, clinical genetics, pharmacogenomics, and reference testing, enabling the company to serve both high-volume and complex diagnostic demand.
Quest Diagnostics accounted for 14.5% of global revenue in 2025. The company's health-system relationships, national laboratory network, and specialty-menu expansion support its ability to deepen participation in hereditary genetics, infectious disease, and molecular testing while integrating regional outreach opportunities.
Natera held a 7.0% revenue share in 2025. Its concentration in cell-free DNA applications for oncology, reproductive health, and transplant surveillance places the company in diagnostic categories where clinical validation, physician adoption, and managed-care coverage are important barriers to entry.
Mayo Clinic Laboratories competes through its integration of clinical research, specialized medical expertise, and high-complexity esoteric testing. Its academic reference-laboratory model is particularly relevant in rare disease and other applications where clinical interpretation and the ability to translate emerging science are core differentiators.
Myriad Genetics maintains a focused position in hereditary cancer, reproductive genetics, and pharmacogenomics. Established physician and payer relationships provide commercial continuity in applications where multi-gene panel breadth, evidence generation, and reimbursement experience are difficult for new entrants to replicate.
Recent Industry Developments
On September 19, 2025, the U.S. Food and Drug Administration published a final rule implementing the vacatur of its prior laboratory developed tests oversight rule and returning the regulatory text to its pre-May 2024 form [5]U.S. Food and Drug Administration. "Regulation Identification Number 0910-AJ05 Medical Devices; Laboratory Developed Tests; Implementation of Vacatur." federalregister.gov. The action removed a significant source of regulatory uncertainty for laboratories considering assay-development and portfolio-expansion investments.
On September 15, 2025, Labcorp completed its acquisition of select BioReference Health oncology and related clinical-testing assets for up to USD 225 million, including USD 192.5 million paid at closing [6]Labcorp. "Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses." ir.labcorp.com. The transaction expands Labcorp's oncology testing capabilities and illustrates the strategic value assigned to specialized cancer diagnostic infrastructure.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →